Weight Loss Study: Genetics and Response to Naltrexone/Bupropion — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Weight Loss Study: Genetics and Response to Naltrexone/Bupropion — Stella

Recruiting

Back to Obesity trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

United States

Columbia University Medical Center, New York, New York

Key details

Phase

Post-approval study

Sponsor

Columbia University

Collaborators

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Enrollment target

~120 participants

Started

June 2023

Primary completion

June 2027

Age range

18 Years – 65 Years

Last updated May 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov